{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-274068","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.845365+00:00","generated_at":"2026-06-08T06:48:17.058031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Wave Life Sciences Q3 net income $7.3M; initiates first RNA editing clinical program, WVE-006","bullets":["Net income of $7.3M vs net loss of $39.0M YoY; revenue increase driven by $48.9M in collaboration milestones.","Cash $139.9M as of Sep 30, plus $7M milestone received in 4Q; runway into 2025.","Initiated RestorAATion clinical program for WVE-006 (RNA editing for AATD); dosing in 4Q 2023, proof-of-mechanism data in 2024.","Enrolled 30mg multi-dose cohort of SELECT-HD for WVE-003; data in 2Q 2024 to enable Takeda opt-in.","Preclinical INHBE siRNA data for obesity; clinical candidate selection in 4Q 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-274068","json":"https://secwatch.observer/filing/0001193125-23-274068.json","markdown":"https://secwatch.observer/filing/0001193125-23-274068.md","text":"https://secwatch.observer/filing/0001193125-23-274068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523274068/0001193125-23-274068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523274068/d243880d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:48:17.058031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1594bb69773783d71c4599a1ad14f3ed50b86c8a","claim":"Wave Life Sciences Ltd. reported the third quarter ended September 30, 2023 results: net income Cash and cash equivalents of $140 million as of September 30, 2023.","evidence_excerpt":"On November 9, 2023, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523274068/0001193125-23-274068-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Cash and cash equivalents of $140 million as of September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}